January 5, 2018
FDA: PharMEDium recalls 55 lots of compounded sterile drugs
Editor's Note
The Food and Drug Administration on January 2 announced the recall by PharMEDium Services (Lake Forest, Illinois) of 55 lots (impacting 25,327 units) of compounded sterile drug products because of a lack of sterility assurance.
The recalled products were manufactured in PharMEDium’s Memphis location and distributed nationwide to hospitals and clinics.
Posted 01/02/2018] AUDIENCE: Risk Manager, Pharmacy ISSUE: PharMEDium Services is voluntarily recalling certain lots of drug products to the hospital/user level due to a lack of assurance of sterility. Administration of a drug product intended to be sterile that is not sterile could result in serious infections that may be life-threatening.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement